Claims
Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.
The randomized, double-blind LoDoCo2 trial testing low-dose colchicine 0.5 mg/day versus placebo in patients with chronic coronary disease: its design, cardiovascular event outcomes, subgroup findings, and interpretation. Not for other colchicine cardiovascular trials such as COLCOT or CLEAR SYNERGY.
Contribute
If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.